MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension.

Trial Profile

MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension.

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 26 Jun 2015

At a glance

  • Drugs Tasimelteon (Primary)
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms MAGELLAN
  • Most Recent Events

    • 31 Jan 2013 Vanda Pharmaceuticals has discontinued all tasimelteon activities in the major depressive disorder indication based on the proof of concept study results, according to a company media release.
    • 31 Jan 2013 Status changed from active, no longer recruiting to discontinued, according to information in a Vanda Pharmaceuticals media release.
    • 31 Jan 2013 Results published in a Vanda Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top